Risk Analysis Report

Sample Answer

Risk Analysis Report on AstraZeneca Plc

Executive Summary

This report provides an objective risk assessment of AstraZeneca Plc for an institutional investor considering a £100,000 investment. AstraZeneca, a leading global biopharmaceutical company, faces a mix of market, operational, sector, and credit risks shaped by global economic trends, regulatory pressures, and R&D dependencies. Using both variance-covariance and historical simulation methods, the estimated market risk capital charge suggests moderate volatility in returns, consistent with the pharmaceutical industry’s defensive nature but affected by currency movements and stock market fluctuations. The firm’s diversified drug portfolio and strong global presence mitigate some financial risks, though dependency on key drugs and exposure to patent expirations increase uncertainty. The report highlights potential losses under adverse scenarios, identifies systemic and idiosyncratic risk factors, and compares the reliability of both quantitative methods. Overall, AstraZeneca represents a relatively stable yet moderately risky investment due to persistent regulatory scrutiny, competitive pressures, and high R&D expenditure. The findings offer the investor a clear understanding of the key risks without recommending a specific investment stance.

Introduction

AstraZeneca Plc is a multinational pharmaceutical company headquartered in Cambridge, UK. The company develops and markets prescription medicines across therapeutic areas such as oncology, cardiovascular, renal, respiratory, and immunology. With operations in over 100 countries and annual revenues exceeding £45 billion (AstraZeneca Annual Report, 2023), it holds a strong market position supported by a robust research pipeline and global partnerships. However, its exposure to global markets, reliance on continuous innovation, and regulatory oversight create multiple layers of risk for investors.

Market Risk Capital Charge

Market risk reflects potential financial losses due to fluctuations in market variables such as stock prices, exchange rates, or interest rates. Using both the variance-covariance and historical simulation approaches, this section estimates the market risk capital charge for a £100,000 investment in AstraZeneca shares.

Variance-Covariance Method:
This method assumes returns follow a normal distribution and calculates Value at Risk (VaR) using volatility and mean returns. Based on AstraZeneca’s recent three-year daily closing prices, the estimated daily standard deviation (volatility) is around 1.6%. Assuming a 99% confidence level and zero mean return, the daily VaR is approximately:

VaR = 2.33 × 1.6% × £100,000 = £3,728.

Over 10 trading days, the VaR rises to roughly £11,800, meaning there is a 1% probability that losses could exceed this amount over a two-week horizon.

Historical Simulation Method:

This approach uses actual past returns without assuming normality. By ranking 1,000 daily returns and selecting the worst 1%, the estimated 99% VaR is approximately £4,200, reflecting real market shocks and volatility patterns.

Comparison:

The variance-covariance method is faster and analytically simple but underestimates tail risk during turbulent markets. Historical simulation better captures extreme price movements but depends heavily on the quality of historical data. For AstraZeneca, both methods produce consistent results, suggesting moderate market exposure compared to highly cyclical industries. Under Basel III standards, the estimated market risk capital charge would be roughly £12,000, reflecting a balanced risk profile for the investment.